The Paris-based pharma behemoth, Sanofi-Aventis, led the second-largest health-care acquisition of 2010 with its proposed purchase of Genzyme Corp., one of the world’s leading biotech players. The European Union has recently announced its approval for the proposed $18.5 billion deal; however, the deal has been held up as Genzyme considers the $69 per share offer as too low. Industry insiders speculate that this deal will soon be worked out.

January 28, 2011

2 Min Read
Understanding the Impact of a Sanofi-Aventis and Genzyme Merger: PharmaLive Special Report

Product diversification remains a significant growth strategy in the pharma world, as demonstrated by 2010’s largest healthcare M&A transaction, Novartis AG’s acquisition of Alcon Inc. For a total of $51.6 billion, Novartis will merge Alcon into its fold and become the premiere player in the worldwide eye-health arena.

Alcon and Novartis have attractive worldwide eye-care activities, each offering its own competitive positions in highly complementary segments that combined cover more than 70% of the global vision-care market. Aligning these strengths will create an offering of even more compelling products for patients around the globe. According to Novartis, the new eye-care division will have enhanced opportunities to accelerate expansion in high-growth regions, generate greater value from combined product portfolios, and capitalize on strengthened R&D capabilities.

The merger is anticipated to be finalized during the first half of 2011. Implementation is expected to take six months from the closing of the merger. Following the completed merger, Alcon will be the new eye-care division of Novartis. The business will include CIBA Vision and ophthalmic medicines.

Boston Scientific continues to show commitment to providing the broadest portfolio of less-invasive devices for cardiovascular care. Boston Scientific recently acquired Atritech, a privately held company based in Plymouth, Minn. This deal is centered around Atritech's newest product, a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The $375 million deal is anticipated to be completed in the first quarter of 2011.

More information is available in the PharmaLive special report Mergers & Acquisitions, Partnerships, & Collaborations Review of 2010 & Outlook. 
 
For additional information, e-mail Sandra Baker, or call her at 215/944-9836. 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like